7,12-Dimethylbenz[A]anthracene induces sertoli-leydig-cell tumors in the follicle-depleted ovaries of mice treated with 4-vinylcyclohexene diepoxide

Comparative Medicine

Volumn 60, Issue 1, 2010, Pages 10-17

  Craig, Zelieann R ^a   Davis, John R ^b   Marion, Samuel L ^c   Barton, Jennifer K ^d   Hoyer, Patricia B ^c  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d University of Arizona   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 VINYLCYCLOHEXENE DIEPOXIDE; 7,12 DIMETHYLBENZ[A]ANTHRACENE; CYTOKERATIN 7; EPOXIDE; INHIBIN; SESAME SEED OIL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; GRANULOSA CELL; HISTOPATHOLOGY; INCIDENCE; LEYDIG CELL TUMOR; MENOPAUSE; MOUSE; NONHUMAN; OVARY; OVARY FOLLICLE CELL; OVARY INSUFFICIENCY; OVARY TUMOR; SERTOLI CELL TUMOR;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CARCINOGENS; CYCLOHEXENES; FEMALE; IMMUNOHISTOCHEMISTRY; INHIBINS; KERATIN-7; MICE; OVARIAN FOLLICLE; OVARIAN NEOPLASMS; SERTOLI-LEYDIG CELL TUMOR; VINYL COMPOUNDS;

EID: 77749239978     PISSN: 15320820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Alison RH, Morgan KT. 1987. Ovarian neoplasms in F344 rats and B6C3F1 mice. Environ Health Perspect 73:91-106.
2. American Cancer Society. [Internet]. Ovarian cancer. [Cited Oct 2006]. Available at http://documents.cancer.org/114.00/114.00.pdf.
3. Birken S, O'Connor J, Kovalevskaya G, Lobel L. 2000. Gonadotropins and menopause: new markers, p 61-73. In: Lobo RA, Kelsey J, Marcus R, editors. Menopause: biology and pathobiology. San Diego (CA): Academic Press.
4. Burger HG. 2000. Perimenopausal changes in FSH, the inhibins, and the circulating steroid hormone milieu, p 147. In: Lobo RA, Kelsey J, Marcus R, editors. Menopause: biology and pathobiology. San Diego (CA): Academic Press.
5. Buters J, Quintanilla-Martinez L, Schober W, Soballa VJ, Hintermair J, Wolff T, Gonzalez FJ, Greim H. 2003. CYP1B1 determined susceptibility to low doses of 7,12-dimethylbenz[a]anthracene-induced ovarian cancers in mice: correlation of CYP1B1-mediated DNA adducts with carcinogenicity. Carcinogenesis 24:327-334.
6. Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, Vergote I. 2006. Ovarian cancer. Crit Rev Oncol Hematol 60:159-179.
7. Copeland NG, Gilbert DJ, Cho BC, Donovan PJ, Jenkins NA, Cosman D, Anderson D, Lyman SD, Williams DE. 1990. Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles. Cell 63:175-183.
8. Crist KA, Zhang Z, You M, Gunning WT, Conran PB, Steele VE, Lubet RA. 2005. Characterization of rat ovarian adenocarcinomas developed in response to direct instillation of 7,12-dimethylbenz[a]anthracene (DMBA)-coated suture. Carcinogenesis 26:951-957.
9. Daniel FB, Joyce NJ. 1984. 7,12-dimethylbenz[a]anthracene-DNA adducts in Sprague-Dawley and Long-evans female rats: the relationship of DNA adducts to mammary cancer. Carcinogenesis 5:1021-1026.
10. Danilovich N, Roy I, Sairam MR. 2001. Ovarian pathology and high incidence of sex cord tumors in follitropin receptor knockout (FORKO) mice. Endocrinology 142:3673-3684.
11. Gonzalez FJ. 2001. The use of gene knockout mice to unravel the mechanisms of toxicity and chemical carcinogenesis. Toxicol Lett 120:199-208.
12. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK, editors. 2009. [Internet]. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Based on November 2008 SEER data submission, posted to the SEER web site. [Cited May 2009]. Available at http://www.seer.cancer.gov/csr/1975-2006/index.html.
13. Hoyer PB, Davis JR, Bedrnicek JB, Marion SL, Christian PJ, Barton JK, Brewer MA. 2009. Ovarian neoplasm developtment by 7,12-dimethylbenz[a] anthracene (DMBA) in a chemically-induced rat model of ovarian failure. Gynecol Oncol 112:610-615.
14. Hu X, Christian PJ, Sipes IG, Hoyer PB. 2001. Expression and redistribution of cellular bad, bax, and bcl-X(L) protein is associated with VCD-induced ovotoxicity in rats. Biol Reprod 65:1489-1495.
15. Hu X, Christian PJ, Thompson KE, Sipes IG, Hoyer PB. 2001. Apoptosis induced in rats by 4-vinylcyclohexene diepoxide is associated with activation of the caspase cascade. Biol Reprod 65:87-93.
16. Institute of Laboratory Animal Resources. 1996. Guide for the care and use of laboratory animals. Washington (DC): National Academies Press.
17. Ishimura K, Matsuda H, Tatsumi H, Fujita H, Terada N, Kitamura Y. 1986. Ultrastructural changes in the ovaries of Sl/Slt mutant mice, showing developmental deficiency of follicles and tubular adenomas. Arch Histol Jpn 49:379-389.
18. Judson PL, Boente MP. 2003. Ovarian sex cord - stromal tumors, p 231. In: Ozols RF, editor. Ovarian cancer. Hamilton (Canada): BC Decker.
19. Kanter EM, Walker RM, Marion SL, Brewer M, Hoyer PB, Barton JK. 2006. Dual modality imaging of a novel rat model of ovarian carcinogenesis. J Biomed Opt 11:041123.
20. Keck M, Romero-Aleshire MJ, Cai Q, Hoyer PB, Brooks HL. 2007. Hormonal status affects the progression of STZ-induced diabetes and diabetic renal damage in the VCD mouse model of menopause. Am J Physiol Renal Physiol 293:F193-F199.
21. Krarup T. 1969. Oocyte destruction and ovarian tumorigenesis after direct application of a chemical carcinogen (9:10-dimethyl-1:2-benzanthrene) to the mouse ovary. Int J Cancer 4:61-75.
22. Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Fre E 3rd. 2003. Cancer medicine. Hamilton (Canada): BC Decker.
23. Kuwahara I. 1967. Experimental induction of ovarian tumors in mice treated with single administration of 7,12-dimethylbenz[a]anthracene, and its histopathological observation. Gann 58:253-266.
24. Lohff JC, Christian PJ, Marion SL, Arrandale A, Hoyer PB. 2005. Characterization of cyclicity and hormonal profile with impending ovarian failure in a novel chemical-induced mouse model of perimenopause. Comp Med 55:523-527.
25. Lohff JC, Christian PJ, Marion SL, Hoyer PB. 2006. Effect of duration of dosing on onset of ovarian failure in a chemical-induced mouse model of perimenopause. Menopause 13:482-488.
26. Mattison DR, Schulman JD. 1980. How xenobiotic chemicals can destroy oocytes. Contemp Obstet Gynecol 15:157-169.
27. Mayer LP, Devine PJ, Dyer CA, Hoyer PB. 2004. The follicle-deplete ovary produces androgen. Biol Reprod 71:130-138.
28. Mayer LP, Dyer CA, Eastgard RL, Hoyer PB, Banka CL. 2005. Atherosclerotic lesion development in a novel ovary-intact mouse model of perimenopause. Arterioscler Thromb Vasc Biol 25:1910-1916.
29. McCluggage WG. 2002. Recent advances in immunohistochemistry in gynaecological pathology. Histopathology 40:309-326.
30. Mintz B, Russell ES. 1957. Gene-induced embryological modifications of primordial germ cells in the mouse. J Exp Zool 134:207-237.
31. Miyata M, Kudo G, Lee YH, Yang TJ, Gelboin HV, Fernandez-Salguero P, Kimura S, Gonzalez FJ. 1999. Targeted disruption of the microsomal epoxide hydrolase gene, microsomal epoxide hydrolase is required for the carcinogenic activity of 7,12-dimethylbenz[a]anthracene. J Biol Chem 274:23963-23968.
32. Murphy ED. 1972. Hyperplasia and early neoplastic changes in the ovaries of mice after genic deletion of germ cells. J Natl Cancer Inst 48:1283-1295.
33. v genotype. Cancer Res 33:721-723.
34. Murphy ED, Russell ES. 1963. Ovarian tumorigenesis following genic deletion of germ cells in hybrid mice. Acta Unio Int Contra Cancrum 19:779-782.
35. Nicol CJ, Yoon M, Ward JM, Yamashita M, Fukamachi K, Peters JM, Gonzalez FJ. 2004. PPARgamma influences susceptibility to DMBA-induced mammary, ovarian, and skin carcinogenesis. Carcinogenesis 25:1747-1755.
36. Prejean JD, Peckham JC, Casey AE, Griswold DP, Weisburger EK, Weisburger JH. 1973. Spontaneous tumors in Sprague - Dawley rats and Swiss mice. Cancer Res 33:2768-2773.
37. Reith AD, Rottapel R, Giddens E, Brady C, Forrester L, Bernstein A. 1990. W-mutant mice with mild or severe developmental defects contain distinct point mutations in the kinase domain of the c-kit receptor. Genes Dev 4:390-400.
38. Rivera Z, Hoying JB, Hoyer PB. 2008. Residual ovarian tissue of follicle-depleted mice expresses genes for androgen synthesis and metabolism of xenobiotic compounds. Biol Reprod 78:112.
39. Romero-Aleshire MJ, Diamond-Stanic MK, Hasty AH, Hoyer PB, Brooks HL. 2009. Loss of ovarian function in the VCD mouse model of menopause leads to insulin resistance and a rapid progression into the metabolic syndrome. Am J Physiol Regul Integr Comp Physiol 297:R587-R592.
40. Salazar H, Godwin AK, Daly MB, Laub PB, Hogan WM, Rosenblum N, Boente MP, Lynch HT, Hamilton TC. 1996. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 88:1810-1820.
41. Salehi F, Dunfield L, Phillips KP, Krewski D, Vanderhyden BC. 2008. Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. J Toxicol Environ Health B Crit Rev 11:301-321.
42. Springer LN, McAsey ME, Flaws JA, Tilly JL, Sipes IG, Hoyer PB. 1996. Involvement of apoptosis in 4-vinylcyclohexene diepoxide-induced ovotoxicity in rats. Toxicol Appl Pharmacol 139:394-401.
43. Stewart SL, Querec TD, Ochman AR, Gruver BN, Bao R, Babb JS, Wong TS, Koutroukides T, Pinnola AD, Klein-Szanto A, Hamilton TC, Patriotis C. 2004. Characterization of a carcinogenesis rat model of ovarian preneoplasia and neoplasia. Cancer Res 64:8177-8183.
44. Takai Y, Cannign J, Perez GI, Pru JK, Schlezinger JJ, Sherr DH, Kolesnick RN, Yuan J, Flavell RA, Korsmeyer SJ, Tilly JL. 2003. Bax, caspase 2, and caspase 3 are required for ovarian follicle loss caused by 4-vinylcyclohexene diepoxide exposure of female mice in vivo. Endocrinology 144:69-74.
45. Terada N, Kitamura Y, Namiki M, Kuroda H, Ito M, Takatsuka D, Matsumoto K. 1984. Production of androgens and estrogens by tubular adenomas which developed in ovaries of mutant mice of Sl/Slt genotype. Cancer Res 44:1827-1830.
46. Vanderhyden BC. 2005. Loss of ovarian function and the risk of ovarian cancer. Cell Tissue Res 322:117-124.
47. Vanderhyden BC, Shaw TJ, Ethier J. 2003. Animal models of ovarian cancer. Reprod Biol Endocrinol 1:67.
48. Wang Y, Zhang Z, Lu Y, Yao R, Jia D, Wen W, LaRegina M, Crist K, Lubet R, You M. 2008. Enhanced susceptibility to chemical induction of ovarian tumors in mice with a germline p53 mutation. Mol Cancer Res 6:99-109.
49. Weiss NS, Homonchuk T, Young JLJ. 1977. Incidence of the histological types of ovarian cancer: the US Third National Cancer Survey, 1969-1971. Gynecol Oncol 5:161-167.
50. Williams JK. 2005. A mouse model of the perimenopausal transition: importance for cardiovascular research. Arterioscler Thromb Vasc Biol 25:1765-1766.
51. Wright LE, Christian PJ, Rivera Z, Van Alstine WG, Funk JL, Bouxsein ML, Hoyer PB. 2008. Comparison of skeletal effects of ovariectomy versus chemical-induced ovarian failure in mice. J Bone Miner Res 23:1296-1303.